X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (14979) 14979
Book Chapter (81) 81
Magazine Article (51) 51
Dissertation (49) 49
Newspaper Article (29) 29
Publication (17) 17
Conference Proceeding (16) 16
Book / eBook (6) 6
Government Document (6) 6
Web Resource (6) 6
Reference (4) 4
Trade Publication Article (2) 2
Book Review (1) 1
Newsletter (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
trastuzumab (12571) 12571
humans (10020) 10020
female (7551) 7551
oncology (7382) 7382
breast cancer (6303) 6303
breast neoplasms - drug therapy (4930) 4930
chemotherapy (3702) 3702
cancer (3597) 3597
breast neoplasms - pathology (3284) 3284
middle aged (3158) 3158
antibodies, monoclonal, humanized (2973) 2973
receptor, erbb-2 - metabolism (2902) 2902
her2 (2766) 2766
antineoplastic agents - therapeutic use (2559) 2559
adult (2521) 2521
aged (2484) 2484
therapy (2328) 2328
breast neoplasms - metabolism (2083) 2083
animals (2011) 2011
antineoplastic combined chemotherapy protocols - therapeutic use (1961) 1961
antibodies, monoclonal - therapeutic use (1810) 1810
cell line, tumor (1692) 1692
treatment outcome (1681) 1681
breast neoplasms - genetics (1620) 1620
metastasis (1611) 1611
survival (1585) 1585
adjuvant chemotherapy (1557) 1557
care and treatment (1544) 1544
receptor, erbb-2 - genetics (1530) 1530
prognosis (1523) 1523
monoclonal-antibody (1457) 1457
breast-cancer (1434) 1434
skin and connective tissue diseases (1430) 1430
expression (1395) 1395
erbb-2 protein (1389) 1389
tumors (1349) 1349
mice (1291) 1291
epidermal growth factor (1255) 1255
research (1253) 1253
medicine & public health (1195) 1195
immunohistochemistry (1194) 1194
cancer therapies (1127) 1127
receptor, erbb-2 - antagonists & inhibitors (1123) 1123
analysis (1117) 1117
lapatinib (1113) 1113
pharmacology & pharmacy (1104) 1104
antineoplastic agents - pharmacology (1074) 1074
male (974) 974
aged, 80 and over (950) 950
disease-free survival (923) 923
paclitaxel (919) 919
neoplasm staging (911) 911
docetaxel (908) 908
antibodies, monoclonal - administration & dosage (895) 895
health aspects (893) 893
drug therapy (884) 884
antibodies, monoclonal, humanized - therapeutic use (876) 876
efficacy (875) 875
breast neoplasms - mortality (871) 871
gene amplification (869) 869
antineoplastic agents - adverse effects (866) 866
metastatic breast-cancer (860) 860
chemotherapy, adjuvant (859) 859
open-label (853) 853
resistance (823) 823
receptor (820) 820
monoclonal antibodies (817) 817
patients (814) 814
pertuzumab (799) 799
phase-ii (790) 790
neoplasms (778) 778
receptor, erbb-2 - analysis (769) 769
antibodies, monoclonal, humanized - administration & dosage (764) 764
retrospective studies (764) 764
neoadjuvant therapy (761) 761
antineoplastic agents (756) 756
growth-factor receptor (754) 754
neoplasm metastasis (750) 750
cardiotoxicity (747) 747
trial (741) 741
clinical trials (706) 706
antibodies, monoclonal - pharmacology (704) 704
carcinoma (704) 704
hematology, oncology and palliative medicine (697) 697
metastases (692) 692
women (691) 691
breast neoplasms - therapy (689) 689
proteins (687) 687
amplification (686) 686
antineoplastic agents - administration & dosage (684) 684
cell biology (681) 681
trastuzumab resistance (676) 676
herceptin (666) 666
gene expression (652) 652
antimitotic agents (650) 650
safety (642) 642
trastuzumab - administration & dosage (641) 641
surgery (634) 634
trastuzumab - therapeutic use (633) 633
growth (624) 624
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (14346) 14346
Japanese (311) 311
French (307) 307
German (179) 179
Chinese (101) 101
Spanish (58) 58
Russian (50) 50
Portuguese (44) 44
Polish (38) 38
Italian (30) 30
Hungarian (18) 18
Czech (16) 16
Korean (16) 16
Norwegian (9) 9
Turkish (9) 9
Dutch (8) 8
Danish (5) 5
Finnish (5) 5
Swedish (5) 5
Hebrew (4) 4
Slovak (3) 3
Slovenian (3) 3
Bosnian (2) 2
Serbian (2) 2
Bulgarian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nippon Shōkakibyō Gakkai zasshi, ISSN 0446-6586, 2017, Volume 114, Issue 1, pp. 59 - 68
Journal Article
BMC cancer, ISSN 1471-2407, 2019, Volume 19, Issue 1, pp. 973 - 15
Journal Article
Annals of oncology, ISSN 0923-7534, 2018, Volume 29, Issue 3, pp. 646 - 653
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 389, Issue 10075, pp. 1195 - 1205
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 12/2017, Volume 83, Issue 12, pp. 2767 - 2777
Aims We conducted population pharmacokinetic (PopPK) and exposure–response analyses for trastuzumab emtansine (T‐DM1), to assess the need for T‐DM1 dose... 
population pharmacokinetics (PopPK) | exposure–response (E‐R) | trastuzumab emtansine (T‐DM1) | metastatic breast cancer | exposure–response (E-R) | trastuzumab emtansine (T-DM1) | exposure-response (E-R) | SOLID TUMORS | MODELS | CAUSAL INFERENCE | PHARMACOLOGY | PHARMACOLOGY & PHARMACY | GUIDE | Antineoplastic Agents, Immunological - administration & dosage | Antineoplastic Agents, Immunological - pharmacokinetics | Area Under Curve | Trastuzumab - pharmacokinetics | Humans | Receptor, ErbB-2 - metabolism | Ado-Trastuzumab Emtansine | Metabolic Clearance Rate | Trastuzumab - blood | Antineoplastic Agents, Immunological - blood | Breast Neoplasms - enzymology | Tubulin Modulators - administration & dosage | Female | Receptor, ErbB-2 - antagonists & inhibitors | Maytansine - blood | Tubulin Modulators - blood | Maytansine - adverse effects | Tubulin Modulators - adverse effects | Risk Assessment | Maytansine - analogs & derivatives | Tubulin Modulators - pharmacokinetics | Kaplan-Meier Estimate | Proportional Hazards Models | Trastuzumab - adverse effects | Logistic Models | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Agents, Immunological - adverse effects | Maytansine - administration & dosage | Models, Biological | Maytansine - pharmacokinetics | Breast Neoplasms - blood | Breast Neoplasms - mortality | Infusions, Intravenous | Nonlinear Dynamics | Pharmacokinetic Dynamic Relationships
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 917 - 928
Summary Background CT-P6 is a proposed biosimilar to reference trastuzumab. In this study, we aimed to establish equivalence of CT-P6 to reference trastuzumab... 
Hematology, Oncology and Palliative Medicine | NEOADJUVANT TREATMENT | EPIRUBICIN | ONCOLOGY | CONTROLLED SUPERIORITY TRIAL | OPEN-LABEL | PLUS TRASTUZUMAB | CHEMOTHERAPY | BIOSIMILAR MONOCLONAL-ANTIBODIES | PATHOLOGICAL COMPLETE RESPONSE | ADJUVANT TRASTUZUMAB | PACLITAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Adenocarcinoma - pathology | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Breast Neoplasms - chemistry | Fluorouracil - administration & dosage | Mastectomy | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Adenocarcinoma - chemistry | Biosimilar Pharmaceuticals - therapeutic use | Biosimilar Pharmaceuticals - administration & dosage | Double-Blind Method | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Biosimilar Pharmaceuticals - adverse effects | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Receptor, ErbB-2 - analysis | Neoplasm Staging | Adenocarcinoma - surgery | Antimitotic agents | Medical colleges | Adjuvant treatment | Clinical trials | Breast cancer | Product development | Comparative analysis | Antineoplastic agents | Cancer
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 2, pp. 122 - 131
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 4, pp. 545 - 554
Journal Article
Breast cancer research and treatment, ISSN 1573-7217, 2019, Volume 175, Issue 3, pp. 595 - 603
HER2-targeted therapies have substantially improved the outcome of patients with breast cancer, however, they can be associated with cardiac toxicity.... 
HER2-targeted therapy | Medicine & Public Health | Carvedilol | Cardiac safety | Oncology | Breast cancer | Cardiac dysfunction | ADJUVANT CHEMOTHERAPY | PREVENTION | RANDOMIZED-TRIAL | PERTUZUMAB | PLUS TRASTUZUMAB | PACLITAXEL | TRIAL COMPARING DOXORUBICIN | ONCOLOGY | DYSFUNCTION | HER2 | Prospective Studies | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Ado-Trastuzumab Emtansine | Ventricular Dysfunction, Left - chemically induced | Breast Neoplasms - metabolism | Antibodies, Monoclonal, Humanized - administration & dosage | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Adult | Female | Adrenergic beta-Antagonists - therapeutic use | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Molecular Targeted Therapy - adverse effects | Maytansine - analogs & derivatives | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Ventricular Dysfunction, Left - physiopathology | Maytansine - administration & dosage | Pilot Projects | Ventricular Dysfunction, Left - drug therapy | Aged | Neoplasm Staging | Heart | Care and treatment | Cancer patients | Pertuzumab | Cardiac patients | Oncology, Experimental | Research | Cardiology | Adrenergic beta blockers | Heart attack | Cancer | Index Medicus | Clinical Trial
Journal Article